ArticleFrontiers in neuroscience2021
Monoamine Levels and Parkinson's Disease Progression: Evidence From a High-Performance Liquid Chromatography Study.
Article in Frontiers in neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 27 citations in OpenAlex.
- Interactions between gut microbiota and parkinson's disease: the role of tryptophan metabolism.Cell communication and signaling : CCS · 2025Review
- The Determination of Trimethylamine N-Oxide and Organic Acids Connected with Gut Microbiota in the Urine of Parkinson's Disease Patients: A Pilot Study.International journal of molecular sciences · 2025Article
- Review
- Urinary based biomarkers identification and genetic profiling in Parkinson's disease: a systematic review of metabolomic studies.Frontiers in bioinformatics · 2025Article
- Review
- Design and Development of Transient Sensing Devices for Healthcare Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Investigation of the causal association between Parkinson's disease and autoimmune disorders: a bidirectional Mendelian randomization study.Frontiers in immunology · 2024Article
- Real-world evidence on levodopa dose escalation in patients with Parkinson's disease treated with istradefylline.PloS one · 2023Article
- Article
- Genetically predicted circulating levels of glycine, glutamate, and serotonin in relation to the risks of three major neurodegenerative diseases: A Mendelian randomization analysis.Frontiers in aging neuroscience · 2022Article
- Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases.Frontiers in neurology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is associated with dysfunction of monoamine neurotransmitter systems. We investigated changes in the levels of monoamine and their metabolites in PD patients, together with their association to clinical profiles. PD patients and age-matched control subjects (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.